Diabetes Insipidus: Diagnostic and Treatment Approach
Diagnosis
Suspect diabetes insipidus in children presenting with polyuria, polydipsia, failure to thrive, and hypernatremic dehydration with inappropriately low urine osmolality (typically <200 mOsm/kg H₂O), and in adults with unexplained polydipsia and polyuria 1.
Initial Diagnostic Workup
The diagnostic approach begins with measuring serum sodium, serum osmolality, and urine osmolality as the initial biochemical evaluation 1. Key diagnostic findings include:
- Serum osmolality: Usually >300 mOsm/kg H₂O due to hypernatremia
- Urine osmolality: Inappropriately diluted, typically <200 mOsm/kg H₂O (though can be higher in milder cases)
- Urine osmolality < plasma osmolality is the hallmark finding 1
Distinguishing Central from Nephrogenic DI
The water deprivation test followed by desmopressin administration remains the gold standard for differentiating between central DI (CDI), nephrogenic DI (NDI), and primary polydipsia 2, 3. However, newer diagnostic approaches using copeptin measurement (a stable surrogate marker for arginine vasopressin) after osmotic stimulation with hypertonic saline or arginine infusion show higher diagnostic accuracy than traditional water deprivation testing 3, 4, 5.
Perform early genetic testing in patients with clinical symptoms of suspected NDI 1. Specifically:
- Test AVPR2 and AQP2 genes in all symptomatic females 1
- Consider genetic testing using umbilical cord blood in male offspring of known heterozygote female carriers of AVPR2 mutations 1
- Use only laboratories accredited for diagnostic genetic testing 1
Treatment Approach
Central Diabetes Insipidus
Desmopressin (DDAVP) is the primary treatment for CDI 5, 6. The medication replaces the deficient arginine vasopressin and effectively controls polyuria and polydipsia. Close monitoring is essential to avoid hyponatremia from overtreatment.
Nephrogenic Diabetes Insipidus
Treatment for NDI differs fundamentally from CDI and requires a multi-pronged approach:
1. Fluid Management (Critical Foundation)
Ensure free access to fluid at all times 1. This is non-negotiable and forms the cornerstone of NDI management. Infants are particularly vulnerable as they cannot access fluids independently.
2. Nutritional Management
- Provide normal-for-age milk intake (not water) in infants to guarantee adequate caloric intake 1
- Consider tube feeding (nasogastric or gastrostomy) in infants and children with repeated vomiting/dehydration episodes or failure to thrive 1. Approximately 20-30% of children with NDI require tube feeding at some point, though it's rarely continued beyond age 4 years 1
- Mandatory dietetic counseling from a dietitian experienced with NDI 1
3. Dietary Modifications
Monitor and reduce dietary salt and protein intake to decrease renal osmotic load and minimize urine volume 1. However, excessive restriction compromises growth. Specific recommendations 1:
- Infants (0-1 year): 1 g salt/day (0.4 g sodium); protein 1.3-1.8 g/kg/day depending on age
- Children (1-3 years): 2 g salt/day (0.8 g sodium); protein 1.1 g/kg/day
- Children (4-6 years): 3 g salt/day (1.2 g sodium); protein 0.95 g/kg/day
- Children (7-10 years): 5 g salt/day (2 g sodium); protein 0.95 g/kg/day
- Adolescents/Adults (≥11 years): <6 g salt/day (2.4 g sodium); protein <1 g/kg/day
4. Pharmacological Treatment
In symptomatic infants and children with NDI, start treatment with a thiazide diuretic combined with prostaglandin synthesis (COX) inhibitors 1. This is the recommended first-line pharmacological approach.
Mechanism and efficacy:
- Thiazide diuretics induce mild volume depletion, increasing proximal sodium and water reabsorption
- Can reduce diuresis by up to 50% in the short term when combined with low-salt diet 1
- Long-term effects are more moderate 1
Critical monitoring caveat: Drug treatment can be highly effective in infancy, with reported cases of marked hyponatremia in patients who maintained high fluid intake after starting treatment. Close monitoring of fluid balance, weight, and biochemistry is mandatory at treatment initiation 1.
Add amiloride to thiazide in patients who develop thiazide-induced hypokalaemia 1.
Discontinue COX inhibitors once patients reach adulthood (≥18 years) or earlier if full continence is achieved, due to nephrotoxicity concerns 1. Thiazide diuretics may be continued based on patient preference, though many patients tolerate discontinuation well.
Note on desmopressin in NDI: While NDI is characterized by resistance to AVP, high-dose DDAVP may be effective in select cases with residual V2 receptor function 7. Patients with higher urine osmolality on water deprivation testing (>200 mOsm/kg H₂O) and after vasopressin injection (>500 mOsm/kg H₂O) are more likely to respond 7. However, this is not standard first-line therapy.
5. Monitoring and Follow-up
- Evaluate treatment efficacy via urine osmolality, urine output, weight gain, and growth 1
- Perform kidney ultrasound at least every 2 years to monitor for urinary tract dilatation and/or bladder dysfunction from polyuria 1. Hydronephrosis occurs in approximately 34% of NDI patients 1
- Multidisciplinary team follow-up including nephrologist, dietitian, psychologist, social worker, and urologist 1
Common Pitfalls
Misdiagnosing partial NDI as CDI due to partial desmopressin response or misleading MRI findings 8. Always pursue genetic testing when clinical response is atypical.
Hyponatremia from overzealous treatment in infants starting thiazides/COX inhibitors who maintain high fluid intake 1. Requires close initial monitoring.
Inadequate caloric intake in infants preferring water over nutritional fluids 1. This necessitates normal-for-age milk intake rather than free water.
Overlooking reversible causes such as pheochromocytoma that can mimic DI 9.
Excessive dietary restriction compromising growth in children 1. Balance is essential between reducing osmotic load and maintaining adequate nutrition.